Abstract

IN-VIVO STUDIES OF ANTI-PARKINSON ACTIVITY OF ROPINIROLE HYDROCHLORIDE LOADED IN MICROEMULSION FOR BRAIN TARGETING BY INTRANASAL DELIVERY

Shubhrajit Mantry* and Anna Balaji

ABSTRACT

In the present study, we evaluated anti-Parkinson’s activity of Ropinirole hydrochloride loaded in microemulsion via intranasal delivery for brain targeting. All animal experiments were approved and performed in Malla Reddy College of Pharmacy accordance with the guidelines of Institutional Animal Ethics Committee (CPCSEA Registration No: 1217/PO/RE/S/2008). The results of biodistribution studies showed the time profile of Ropinirole Hydrochloride concentration in brain and plasma higher after intranasal (IN) administration of drug-loaded ME as compared to intravenous (IV) administration of PDS. The first finding of our study was that intranasal administration allowed Ropinirole Hydrochloride uptake into the CNS. After the initial 20 min, the drug concentration in the brain was found higher for intranasal delivered microemulsion (0.9334±0.0292μg/ml) than the Intravenous administered PDS (0.1567±0.023 μg/ml). In vivo studies data suggest that the nasal route could exploit to increase the availability of Ropinirole Hydrochloride inside the brain. However, clinical benefits of the formulation developed in this investigation will decide its appropriateness in the clinical practice for the treatment of Parkinson’s disease.

Keywords: Anti-Parkinson activity, Ropinirole Hydrochloride Microemulsion, Brain targeting.